 |
市場調查報告書
商品編碼
2058148
慢性脫髓鞘多發性神經炎（CIDP）：新型療法、未滿足的需求和TPP洞察報告，2026年Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026 |
||||||
市場概覽
- 預計到 2035 年，義大利 CIDP 市場規模將從約 1.45 億美元成長到 3.75 億美元。
- 市場成長受以下因素支撐：
- 擴大靜脈注射免疫球蛋白（IVIG）、皮下注射免疫球蛋白（SCIG）和標靶免疫療法的應用
- 改善診斷技術和長期疾病管理
- 市場擴張是由慢性病治療需求和先進治療方法的日益普及所驅動的。
- 未來的成長取決於新型免疫調節療法和長期疾病管理策略的改進。
慢性脫髓鞘多發性神經炎（CIDP）的新治療方法和TPP見解
Thelansis 發布的「慢性脫髓鞘多發性神經炎(CIDP)：新型療法、未滿足的需求和 TPP 洞察報告，2026」對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解領袖。
慢性脫髓鞘多發性神經炎（CIDP）概述
慢性脫髓鞘多發性神經炎(CIDP) 是一種免疫介導的周邊神經病變，由 T 細胞和自體抗體引起的髓鞘破壞所致，導致進行性或復發性近端和遠端肢體無力，並伴隨感覺障礙。患者表現為對稱性肌無力、反射消失、步態不穩和感覺障礙，這些症狀會在數月內逐漸加重。診斷包括去髓鞘化的神經傳導檢查、腦脊髓液細胞和白蛋白分離，以及必要時的神經切片檢查。疾病嚴重程度透過殘障評定量表來評估。糖皮質激素、靜脈注射免疫球蛋白和血漿置換是公認的第一線治療方案，皮下注射免疫球蛋白是一種方便的維持治療方案。皮下注射 fgaltigimod 是一種已通過核准治療方法，可減少致病性 IgG 並降低復發風險。治療方案會根據定期神經系統評估結果逐步加強。早期治療和多學科復健有助於維持病情緩解。
主要亮點
- 預計到 2025 年，法國患有 CIDP 的人數將增加到 2035 年的 3,992 人。
- CIDP是一種罕見的自體免疫神經系統疾病，其特徵是進行性肌肉無力和感覺障礙。
- 早期診斷和治療對於預防不可逆的神經損傷和身體殘疾至關重要。
- 免疫球蛋白療法仍是疾病治療的基石。
- 新型分子標靶免疫療法的出現，正拓展疑難雜症的治療選擇。
從對醫生和關鍵意見領袖的調查中獲得的見解：
- 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步豐富了研究成果。
- 調查問卷將根據客戶的要求進行客製化。
交付成果格式：
- PowerPoint簡報
- MS Excel
主要問題
- 詳細的競爭格局趨勢
- 管道分析
- 符合新興治療方法的患者
- 大公司
- 主要作用機制
- 發布日期等的預測
- 臨床試驗趨勢分析
- 目標患者群
- 試驗終點
- 測試設計
- 受試者招募標準等。
- 未滿足的需求和機遇
- 目前主要治療方法的有效性
- 未滿足需求的關鍵領域
- 估算主要未滿足需求的市場規模
- 目標產品概況
- 屬性和級別
- 醫生開立的處方
- 預期患者佔有率
- 關鍵KOL洞察對領先新興治療方法的見解
- 意識
- 預期用途/處理線
- 對主要未滿足需求的滿意度
- KOL評論
目標國家
- G8
- 美國
- EU5
- 法國
- 德國
- 義大利
- 西班牙
- 英國
- 日本
- 中國
大公司
- Takeda
- Kine Sciences Co., Ltd.
- Immunovant Sciences GmbH
- Argenx
- Grifols Therapeutics LLC
- Nuvig Therapeutics, Inc.
- Sanofi
- Kite, A Gilead Company
- Janssen Research &Development, LLC
- Kedrion SpA
目錄
第1章：主要調查結果及分析師說明
- 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。
第2章 競爭情勢
- 目前的治療方法
- 重點
- 診斷和治療過程/演算法
- 主要治療方法概述及KOL洞察
- 新興治療方法
- 重點
- 診斷和治療過程/演算法
- 領先的新興治療方法—概述和KOL洞察
第3章 產品屬性分析
- 重點
- 科學屬性
- 商業性屬性
- 產品定位
第4章：一級市場調查
- 目前治療狀態
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療環境
- 當前挑戰
- 未滿足的需求
- 新興治療方法
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療前景
- 未滿足的需求和關鍵意見領袖的期望
第5章：未滿足的需求和TPP分析
- 新興治療方法的主要未滿足需求和未來成就
- TPP分析與KOL預期
第6章 監理與報銷環境
第7章附錄
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapy and TPP Insights
Thelansis's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview
Chronic Inflammatory Demyelinating Polyneuropathy is an immune-mediated peripheral neuropathy driven by T-cell and autoantibody-mediated myelin destruction, causing progressive or relapsing proximal and distal limb weakness with sensory impairment. Patients present with symmetric weakness, areflexia, gait instability, and sensory disturbance evolving over months. Diagnosis combines nerve conduction studies showing demyelination, CSF cytoalbuminous dissociation, and nerve biopsy when indicated; disability scales reflect severity. Corticosteroids, intravenous immunoglobulin, and plasma exchange are established first-line treatments; subcutaneous immunoglobulin offers convenient maintenance. Subcutaneous efgartigimod is an approved FcRn-targeted option reducing pathogenic IgG and relapse risk. Regular neurological assessments guide therapy escalation. Early treatment and multidisciplinary rehabilitation support sustained remission.
Key Highlights
- In France, the prevalent CIDP population is projected to increase from approximately 3,808 in 2025 to 3,992 by 2035.
- CIDP is a rare autoimmune neurological disorder characterized by progressive weakness and sensory dysfunction.
- Early diagnosis and treatment remain critical to preventing irreversible nerve damage and disability.
- Immunoglobulin therapy continues to represent the cornerstone of disease management.
- Emerging targeted immunotherapies are expanding treatment options for refractory disease.
Market Overview
- The Italy CIDP market is projected to grow from approximately $145 MN to $375 MN by 2035.
- Market growth is supported by:
- Increasing utilization of IVIG, SCIG, and targeted immunotherapies
- Improved diagnosis and long-term disease management
- Market value growth is driven by chronic treatment requirements and increasing adoption of advanced therapies.
- Future growth will depend on novel immune-modulating therapies and improved long-term disease control strategies.
Insights driven by surveys with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
- Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Countries Covered
- G8
- United States
- EU5
- France
- Germany
- Italy
- Spain
- U.K.
- Japan
- China
Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country
Companies Mentioned
- Takeda
- Kine Sciences Co., Ltd.
- Immunovant Sciences GmbH
- Argenx
- Grifols Therapeutics LLC
- Nuvig Therapeutics, Inc.
- Sanofi
- Kite, A Gilead Company
- Janssen Research & Development, LLC
- Kedrion S.p.A.
Table of Contents
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies - profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies - profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
